Marker Therapeutics (MRKR) Cash from Operations (2010 - 2026)
Marker Therapeutics (MRKR) reported Cash from Operations of 1404192.0 for Q1 2026, up 74.47% year-over-year from 804842.08 in Q1 2025, and up 26.1% quarter-over-quarter from 1900106.0 in Q4 2025.
Marker Therapeutics (MRKR) Cash from Operations (2010 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has 17 years of Cash from Operations data on file, last reported at 1404192.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 1404192.0, up 74.47% year-over-year; the trailing twelve-month figure through Mar 2026 was 7918536.0 (up 37.02% YoY), and the FY2025 annual result was 12014081.0, down 10.12% from the prior year.
- Cash from Operations advanced to 1404192.0 in Q1 2026 per MRKR's latest filing, from 1900106.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 4908502.0 in Q3 2023 and troughed at 12226062.0 in Q1 2022.
- A 5-year average of 3984747.71 and a median of 3567570.0 in 2024 frame the typical range for Cash from Operations.
- On a YoY basis, Cash from Operations climbed as much as 193.57% in 2023 and fell as far as 15926.71% in 2023.
- A 5-year view of Cash from Operations shows it stood at 9562337.0 in 2022, then climbed by 12.12% to 8403545.0 in 2023, then jumped by 44.03% to 4703135.0 in 2024, then jumped by 59.6% to 1900106.0 in 2025, then rose by 26.1% to 1404192.0 in 2026.
- Business Quant data shows MRKR's Cash from Operations at 1404192.0 in Q1 2026, 1900106.0 in Q4 2025, and 2735876.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Marker Therapeutics | 28.20 Mn | 28.20 Mn | - | -1.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.40 Mn |
| Mar 31, 2026 | -1.40 Mn |
| Dec 31, 2025 | -1.90 Mn |
| Dec 31, 2025 | -1.90 Mn |
| Sep 30, 2025 | -2.74 Mn |
| Sep 30, 2025 | -2.74 Mn |
| Jun 30, 2025 | -1.88 Mn |
| Jun 30, 2025 | -1.88 Mn |
| Mar 31, 2025 | -5.50 Mn |
| Mar 31, 2025 | -5.50 Mn |
| Dec 31, 2024 | -4.70 Mn |
| Dec 31, 2024 | -4.70 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | -3.57 Mn |
| Jun 30, 2024 | -3.57 Mn |
| Mar 31, 2024 | -3.84 Mn |
| Mar 31, 2024 | -3.84 Mn |
| Dec 31, 2023 | -8.40 Mn |
| Dec 31, 2023 | -8.40 Mn |